



SIGACHI LABORATORIES LIMITED

Corporate Office : 4(1) Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

Date: 3.8.2026

Head Listing & Compliance
Metropolitan Stock Exchange of India Limited
205(A), 2nd floor, Piramal Agastya Corporate Park,
Kamani Junction, LBS Road,
Kurla (West), Mumbai – 400070
Dear Sir,

Sub: Submission of unaudited financial results of the Company for the quarter ended 30th June, 2026 along with the Limited review report – Outcome of the Board meeting - Reg.

Ref: Disclosure under Regulation 30 & 33 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Reg.

Pursuant to Regulation 33 and Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its Meeting held today i.e., on Monday, 3rd August, 2026 had inter-alia considered transacted and approved the following items of business:

1. Approved the unaudited financial results along with Segment Results for the quarter ended 30th June, 2026 with limited review report issued by the statutory auditors'.
2. Based on the recommendation of the Nomination and remuneration Committee, the board recommended the reappointment of Sri. P.C. Sai Babu (DIN:10275666) as Non-Executive Non Independent director of the company, who retires by rotation and eligible for reappointment subject to the approval of shareholders at the ensuing Annual General Meeting.
3. Approved the reappointment of Ms. Sridevi Madati (DIN:02446610) as Independent Women Director of the company for second term of five (5) consecutive years with effect from 24.9.2026, subject to the approval of members at the ensuing AGM.
3. Approved the Secretarial Audit Report for the year ended 31.3.2026 issued by Secretarial Auditors' of the company.
4. Approved the Directors report along with the corporate governance reports and other annexure's.



SIGACHI LABORATORIES LIMITED

Corporate Office: 411 Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph.: 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACC8220M1Z4 CIN: L24230TG1994PLC018786

5. Approved the Notice of the 32nd Annual General Meeting (AGM) and the AGM will be held on Tuesday, the 29th day of September, 2026 at 4.00 P.M. through Video Conferencing (VC) / Other Audio Visual Means ('OAVM') and also approved the 32nd Annual Report for the year 2025 - 2026.
6. The Register of Members and Share Transfer Registers will be closed from Wednesday, 23rd September, 2026 to Tuesday, 29th September, 2026 (both the days inclusive) and the record date (cut-off date) will be Tuesday, 22nd September, 2026 and the e-voting period commences from Saturday, 26th September, 2026 (9:00 A.M. IST) to Monday, 28th September, 2026 (5:00 P.M. IST).
7. The board has appointed Mr. N. Mallikarjuna Rao, Chartered Accountant, Partner of M/s. Mallikarjun Rao and Associates, Chartered Accountants as Scrutinizer for the 32nd AGM to be held on 29.9.2026.
8. Assignment of Advance paid for purchase of Flat from Manjeera Constructions Limited to Manjeera Estates Private Limited. The company had paid an amount of Rs.1,50,00,000/- (Rupees one Crore fifty Lakhs only) to M/s. Manjeera Constructions Limited for purchase of flat and its subsidiary company (Manjeera Retail Holdings Private Limited) has defaulted in repayment of loans borrowed by it, which was guaranteed by M/s. Manjeera Constructions Limited and due to default in Repayment of Loans Borrowed By the Subsidiary Company (Manjeera Retail Holdings Private Limited), the Lender (Catalyst Trusteeship Limited) filed an application with the Hon'ble NCLT, Hyderabad, court II, under Insolvency and Bankruptcy Code, 2016.

The Hon'ble NCLT, Hyderabad Court II has admitted the application and the subsidiary company and M/s. Manjeera Constructions Limited were allowed to undergo CIRP. Our Company has filed the claim application with the Hon'ble NCLT, Hyderabad Court II, under Insolvency and Bankruptcy Code, 2016, The Hon'ble NCLT, Hyderabad, Court II has passed an order against Manjeera Constructions Limited and its subsidiary company and the claims made by the persons/entities who paid the advance for purchase of flats have not been admitted by the Hon'ble NCLT.

As per the COC decision the Hon'ble NCLT, Hyderabad Court II, has approved the sale of M/s. Manjeera Constructions Limited to another entity (Consortium of M/s Valentis Laboratories Private Limited & M/s Surya Treasure Island Private Limited) and this entity has paid the consideration and taken over M/s. Manjeera Constructions Limited. Our company has filed an appeal against the orders of Hon'ble NCLT, Hyderabad, Court-II along with some other persons who have also filed claims by appointing an Insolvency Professional on behalf of us and who in turn has appointed an advocate to represent at Hon'ble NCLAT, Chennai and the appeal is yet to be admitted.

In spite of the above issues our company is following up the matter with the former Directors of Manjeera Constructions Limited and its group companies to get some relief. After continuous efforts and follow up, with great difficulty its group company Manjeera Estates Private Limited has come forward for assignment of the MOU entered with Manjeera Constructions Limited and return



SIGACHI LABORATORIES LIMITED

Corporate Office: 411 Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

M/s. Manjeera Estates Private Limited has agreed to pay Rs. 25,00,000/- (Rupees Twenty Five Lakhs Only) and agreed to sell/transfer about 9400 Sq. yards of farm land Plots situated at Sy.No. 231 of the TUSCANY, in Mogudampally Village, Zaheerabad Mandal, Sangareddy District (erstwhile Medak District) Telangana India. As per the Manjeera Estates private Limited, the value of the above farm land plots is about Rs. 90 lakhs – Rs. 1 Crore. Actually the above land inter-alia belongs to M/s. Tree Oil India Limited, which is a subsidiary of M/s. Manjeera Estates Private Limited. In view of the above facts, the board has approved for the receipt of Rs. 25,00,000/- and the Farm lands mentioned herein above to realise atleast a part of the amount so paid and approved the draft MOUs to be entered with M/s. Tree Oil India Limited and M/s. Manjeera Estates Private Limited to proceed further in the matter.

9. Approved the sanction of Loan/ICD of Rs. 40,00,000/- (Rupees Forty Lakhs Only) to Badam Infra Developers Private Limited repayable on demand at the rate of 30% interest per annum.

10. Reconstitution of the audit committee of the company with the following members:

(a) Dr. G. V. Narasimha Rao (b) Sri. G. Mohan Rao, (c) Sri. T. Adinarayana (d) Ms. Sridevi Madati

11. The board has noted that cessation (due to completion of term) of Mrs. Shilpa Bung (DIN:08257931), as an Independent Director of the company with effect from 9.2.2026.

Accordingly, please find enclosed herewith the following:

1. Un-Audited financial Results along with segment results and Limited Review Report for the quarter ended 30th June, 2026.

The Following disclosures are in pursuance to SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated 30.1.2026.

2. Annexure - A relating to Sri. P.C. Sai Babu (DIN:10275666), proposed to be reappointed as the Director of the Company liable to retire by rotation, subject to the approval of members at the ensuing 32nd Annual General Meeting.

3. Annexure – B relating to Ms. Sridevi Madati (DIN:02446610), proposed to be reappointed as the Independent Director of the Company subject to the approval of members at the ensuing 32nd Annual General Meeting.

4. Annexure – C relating to the Assignment of Advance paid for purchase of Flat from Manjeera Constructions Limited to Manjeera Estates Private Limited.



SIGACHI LABORATORIES LIMITED

Corporate Office: 411, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

5. Annexure – D relating to sanction of Loan/ICD of Rs. 40,00,000/- (Rupees Forty Lakhs Only) to Badam Infra Developers Private Limited at the rate of 30% interest per annum.

6. Undertaking for Non-Applicability of Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Statement of Deviation.

Further we wish to inform that following regulations are not applicable to our company:

- a. The company do not have any Non-convertible Instruments (Debt), as such Reg. 52(4) & 52(6) SEBI (LODR) Regulations, 2015 is not applicable to the company.
- b. Reg. 54(2)/(3) SEBI (LODR) Regulations, 2015 – No security cover created as we do not have any secured listed non-convertible debt Instruments.
- c. Non Applicability of SEBI Circular No. SEBI/HO/DDHS/CIR/P/134/2019 dated 13.11.2019 - No requirement for opening a Escrow account – The Company has not issued any municipal debt securities or any other instruments, as such there is no requirement to open a escrow account or create a lien.

Kindly take the above on your records.

Thanking you,

Yours faithfully,
For Sigachi Laboratories Limited

(Lekha Sai Surapaneni)
Company Secretary

The meeting Commenced at 4:00 PM
The Meeting Concluded at 8:00 PM



SIGACHI LABORATORIES LIMITED

Corporate Office: 411 Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACC8220M1Z4 CIN: L24230TG1994PLC018786

Annexure- A

Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Reappointment of Sri. P.C. Sai Babu, as the Non-Executive and Non-Independent Director of the Company liable to retire by rotation, subject to the approval of members at the ensuing 32nd Annual General Meeting.

a.	Reason for change viz. appointment, resignation, removal, death or otherwise	Sri. P.C. Sai Babu, who retires by rotation and being eligible, offers himself for reappointment as Non-Executive and Non-Independent Director. Based on the recommendations of Nomination and Remuneration Committee, the Board of Directors recommends his appointment, as Non-Executive and Non-Independent Director, liable to retire by rotation, which is subject to the approval of members at the ensuing Annual General Meeting of the company.
b.	Date of appointment /reappointment/ cessation (as applicable) & term of appointment /reappointment;	Reappointed by the members at 30 th Annual General meeting of company held on 9.9.2024 liable to retire by rotation.
c.	Brief profile (in case of appointment);	He is a practicing Chartered Accountant with about 38 years of experience. Earlier he had worked in AP Civil Supplies Corporation Limited and in AP Construction Corporation Limited for about 8 years and thus he is having varied experience.
d.	Disclosure of relationships between directors (in case of appointment of a director)	There is no relationships between directors or KMP's
e.	Disclosure pursuant to BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018	Sri. P.C. Sai Babu is not debarred from holding the office of director pursuant to any SEBI order or any such authority.



SIGACHI LABORATORIES LIMITED

Corporate Office: 411 Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

Annexure- B

Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Reappointment of Ms. Sridevi Madati, as the Non-Executive and Independent Women Director of the Company, subject to the approval of members at the ensuing 32nd Annual General Meeting.

a.	Reason for change viz. appointment, resignation, removal, death or otherwise	The first term of Ms. Sridevi Madati as the Non-Executive and Independent Director of the Company comes to an end on 24.9.2026 as such the NRC and the board of Directors, recommend her reappointment as Non-Executive and Independent Women Director which is subject to approval of members at the ensuing AGM of the company.
b.	Date of appointment/ reappointment/cessation (as applicable) & term of appointment/reappointment ;	The members had appointment Ms. Sridevi Madati as the Non-Executive and Independent Women Director of the Company at the 27 th AGM of the company held on 24.9.2021 for a term of 5 years.
c.	Brief profile (in case of appointment);	Ms. Sridevi Madati, aged about 49 years, studied B. Com., and also did her graduation in law and she is Qualified Company Secretary & a member of Institute of Company Secretaries of India (ICSI). She has 22 years experience in corporate, secretarial affairs, legal, regulatory matters, compliance assignments. She is a Practicing Company Secretary and also an Insolvency Professional.
d.	Disclosure of relationships between directors (in case of appointment of a director)	There is no relationships between directors or KMP's
e.	Disclosure pursuant to BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018	Ms. Sridevi Madati is not debarred from holding the office of director pursuant to any SEBI order or any such authority.



SIGACHI LABORATORIES LIMITED

Corporate Office: 411 Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

Annexure - C

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Assignment of Advance paid for purchase of Flat from Manjeera Constructions Limited to Manjeera Estates Private Limited:

Name(s) of parties with whom the agreement is entered	Name: 1. Manjeera Constructions Limited – MOU for purchase of flat was entered. MOUs to be entered with 2. Manjeera Estates Private Limited. 3. Tree Oil India Limited For Assignment
Purpose of entering into the agreement/MOU	To get some amount/property, as M/s. Manjeera Constructions Limited was acquired by another entity under CIRP and the claims made by the parties were not admitted, hence the chance of recovery is very remote. Therefore, after continuous follow up with its erstwhile directors and its group company M/s. Manjeera Estates Private Limited came forward to pay Rs.25 lakhs and transfer about 9400 sq. yards of farm land Plots situated at Sy.No. 231 of the TUSCANY, in Mogudampally Village, Zaheerabad Mandal, Sangareddy District (erstwhile Medak District) Telangana India.
shareholding, if any, in the entity with whom the agreement is executed;	There is no shareholding with the company(s).
significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.	Please refer to point no.8 of the Outcome of the board meeting.
whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship	The said parties are not related to promoter/promoter group/ group companies in any manner.
whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	No.
in case of issuance of shares to the parties, details of issue price, class of shares issued;	Clause not applicable.
any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.;	--



SIGACHI LABORATORIES LIMITED

Corporate Office: 411, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

Annexure - D

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), 2015 for Sanction of Loan:

Details of Borrower	Name: 1. Badam Infra Developers Private Limited Relationship: No relationship of our company with promoter/promoter group/group companies/LLP's/Firms.
Nature of the Loan/ICD	For its business purpose repayable on Demand.
Total amount of Loan/ICD Granted	Rs. 40,00,000/-
Total Amount Outstanding	--
Date of Execution of the Loan/ICD Agreement	Yet to be executed as the Loan/ICD is sanctioned today on 3.8.2026 at the board meeting and the Loan/ICD is yet to be disbursed.
Details of the security provided by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis;	Not applicable as the Loan/ICD is unsecured. It is Guaranteed by its managing Director, Mr. Badam Kishore Kumar.
Whether the said parties are related to promoter/promoter group/group companies in any manner. If yes, nature of relationship;	No promoter/promoter group/group companies in any manner are a related party.

SIGACHI LABORATORIES LIMITED

Regd. Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.

Tel No.: 040 - 23204230/23204273

Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in

CIN: L24230TG1994PLC018786

Statement of Unaudited Financial Results For the Quarter Ended 30th June, 2026

(Rs. in Lakhs)

Sl.No.	Particulars	Quarter ended			Year ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	Income				
1	Revenue from operations	140.22	75.71	127.76	325.75
2	Other income	14.89	23.44	21.71	74.73
3	Total Income (1+2)	155.11	99.15	149.47	400.48
4	Expenses				
	a) Cost of materials consumed	-	-	-	-
	b) Changes in inventories	-	-	-	-
	c) Impairment on Advances	-	-	-	-
	d) Fair Value Losses	-	129.23	-	129.23
	e) Employee benefits expense	11.13	13.19	10.51	47.26
	f) Finance costs	0.21	0.22	-	0.29
	g) Depreciation and amortization expense	5.92	6.06	5.78	25.99
	h) Other expenses	4.55	4.79	3.87	16.81
	Total Expenses	21.81	153.49	20.16	219.58
5	Profit/(Loss) before exceptional items and tax (3-4)	133.30	(54.34)	129.31	180.90
6	Exceptional Items	-	-	-	-
7	Profit/(Loss) before tax (5-6)	133.30	(54.34)	129.31	180.90
8	Tax expense				
	(a) Current tax	9.76	18.35	10.61	54.52
	(b) Deferred tax	13.69	(18.00)	9.70	(7.59)
	Total Tax Expense	23.45	0.35	20.31	46.93
9	Profit/(Loss) for the Period (7-8)	109.85	(54.69)	109.00	133.97
10	Other Comprehensive income (OCI)				
	(a) Items that will not be reclassified to profit or (loss)	201.25	(293.57)	206.16	24.77
	(b) Remeasurement gains/(losses) on defined benefit plans	-	(0.14)	-	(0.14)
	(c) Tax on Items that will not be reclassified to (profit) or loss	28.78	(42.54)	(29.48)	(2.98)
	(d) Items that will be reclassified to profit or (loss)	-	-	-	-
	(e) Items that may be reclassified subsequently to profit or (loss)	-	-	-	-
	Total other Comprehensive income/(loss) for the period, net of tax	172.47	(251.17)	176.68	21.65
	Total Comprehensive income/(loss) (9+10)	282.32	(305.86)	285.68	155.62
11	Paid-up Equity Share Capital (Face Value of Rs.10/- each)	675.31	675.31	675.31	675.31
12	Other Equity	-	-	-	3,357.28
13	Earnings per equity share (of Rs.10/- each) (not annualized (in Rs.))				
	(1) Basic	1.63	(0.81)	1.61	1.98
	(2) Diluted	1.63	(0.81)	1.61	1.98

Segment wise Revenue, Results and Capital Employed For the Quarter Ended 30th June, 2026

(Rs. in Lakhs)

Sl.No	Particulars	Quarter ended			Year ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Segment Revenue				
	a) Bulk Drugs and Intermediates (Lease Rents)	26.50	52.00	25.00	155.00
	b) Investments	128.61	47.15	124.47	245.48
	Total	155.11	99.15	149.47	400.48
	Less: Inter Segment Revenue	-	-	-	-
	Net Sales/Income from Operations	155.11	99.15	149.47	400.48
2	Segment Results Profit/(Loss) before tax and finance costs from each segment				
	a) Bulk Drugs and Intermediates (Lease Rents)	20.01	45.23	18.68	127.40
	b) Investments	128.61	(82.08)	124.47	116.25
	Total	148.62	(36.85)	143.15	243.65
	Less: (i) Finance Costs	0.21	0.22	-	0.29
	(ii) Other Un-allocable Expenditure net off	15.11	17.27	13.84	62.46
	(iii) Un-allocable income	-	-	-	-
	Total Profit/(loss) Before Tax	133.30	(54.34)	129.31	180.90
3	Capital Employed				
	Segment Assets				
	a) Bulk Drugs and Intermediates (leased)	921.44	916.14	699.51	916.14
	b) Investments	3,666.60	3,350.03	3,518.90	3,350.03
	Total (A)	4,588.04	4,266.17	4,218.41	4,266.17
4	Segment Liabilities				
	a) Bulk Drugs and Intermediates (leased)	175.28	178.80	116.12	178.80
	b) Investments	42.10	(0.97)	42.49	(0.97)
	Total (B)	217.38	177.83	158.61	177.83
	Total (A-B)	4,370.66	4,088.34	4,059.80	4,088.34

Notes :

- 1 The above unaudited Financial results as reviewed and recommended by the Audit Committee are considered and approved by the Board of Directors at their respective meetings held on 3rd August, 2026.
- 2 These financial results of the company have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 3 These Financial results have been subjected to limited review by the Statutory Auditors'.
- 4 These Financial Results are available on the Stock Exchange website (www.msei.in) and also on the company's website at (www.slilab.com).

for SIGACHI LABORATORIES LIMITED

Place : Hyderabad
Date : 03.08.2026

(T.R.Sekhar)
Executive Director
DIN:02943146

Independent Auditor's Review Report on the Quarter ended 30th June, 2026 Unaudited Financial Results of the Company pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors of **SIGACHI LABORATORIES LIMITED**

1. We have reviewed the accompanying statement of unaudited financial results of **SIGACHI LABORATORIES LIMITED** ('the Company') for the quarter ended 30th June 2026 attached herewith, being submitted by the Company pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD 1/44/2019 "Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the management and other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Our conclusion on the statement in respect of these matters is not modified with respect to the financial results and other financial information certified by the management.

For M/s. NSVR & ASSOCIATES LLP

Chartered accountants

FRN: 008801.SA.200060



V. Gangadhara Rao N

Partner

Membership No: 219486

UDIN: 26219486QFSPDW9152

Place: Hyderabad

Date : 03-08-2026



SIGACHI LABORATORIES LIMITED

Corporate Office: 411, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN: L24230TG1994PLC018786

Date: 3.8.2026

Head Listing & Compliance
Metropolitan Stock Exchange of India Limited
205(A), 2nd floor, Piramal Agastya Corporate Park,
Kamani Junction, LBS Road,
Kurla (West), Mumbai – 400070

Dear Sir,

Sub: Non-Applicability of Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Reg.

Pursuant to the Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the company had made its public offer (Initial Public Offer IPO) nearly about 25 years back and the Company has fully utilized the proceeds of the IPO for the purpose for which the funds were raised. The company has not raised any fresh issue after Initial public issue - through public issue, rights issue, preferential issue, QIP, etc., Hence, the Statement of deviation(s) or variation(s) is not applicable to the Company

We request you to kindly take note of this information on your record and acknowledge.

Thanking you,

Yours faithfully,
For Sigachi Laboratories Limited

(Lekha Sai Surapaneni)
Company Secretary